Insulet Co. (NASDAQ:PODD – Get Free Report) shares shot up 10.7% during trading on Friday after BTIG Research raised their price target on the stock from $260.00 to $270.00. BTIG Research currently ...

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent ... glucose ...

Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Third ... which makes Omnipod 5 the first and only AID system indicated for both type 1 and type 2 diabetes.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent ... glucose values through wireless bluetooth communication; Omnipod DASH that features ...

Insulet’s Omnipod 5 automated insulin delivery (AID) system has multiple avenues to expand as it has revolutionized the way patients treat their diabetes, including the new indication for Type 2 ...

Insulet (Nasdaq:PODD) shares ticked up today on third-quarter results that came in well ahead of the consensus forecast.

Insulet ( (PODD) ) has released its Q3 earnings. Here is a breakdown of the information Insulet presented to its investors. Insulet ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

PLYMOUTH MEETING, Pa. – AdaptHealth CEO Suzanne Foster is doubling down on efforts to turn around the company’s struggling diabetes business, saying it was “worse” than she initially thought it was.

Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...